| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01209715 Details | 2014-08-01 Interventional | 2 | 0 | Fluticasone Fluticasone-Sal… Salmeterol Xina… Respiratory Asp… COPD | Due to the ubiquitous use of ICS in the treatment of COPD in 2012, it was hard to find the
study population. - | |||
| NCT00746941 Details | 2014-07-31 Interventional | 1/2 | [1 Refs] | 37 | Mefloquine Leukoencephalop… Leukoencephalop… Progressive Mul… | Primary endpoint not achieved From ongoing analysis, it became clear, based on conditional power calculations, that the study would not reach its primary endpoint, a decrease of JC viral load in CSF with mefloquine treatment; therefore, the study was terminated early. | ||
| NCT00499369 Details | 2014-07-31 Interventional | 3 | 72 | Antibodies Antibodies, Mon… Antineoplastic … Bevacizumab Cetuximab Fluorouracil Immunoglobulins Irinotecan Leucovorin Levoleucovorin Colonic Neoplas… Rectal Neoplasm… Recurrence Recurrent Colon… Recurrent Recta… Stage IVA Colon… Stage IVA Recta… Stage IVB Colon… Stage IVB Recta… | Due to inadequate accrual, study was terminated and limited outcome data was reported. Due to inadequate accrual, study was terminated and limited outcome data was reported. | |||
| NCT02127684 Details | 2014-07-30 Interventional | 2 | 0 | Ranibizumab Edema Macular Edema Persistent Diab… | sponsor determined study design would not produce useful results - | |||
| NCT00787852 Details | 2014-07-30 Interventional | 1 | 11 | Albumin-Bound P… Dasatinib Paclitaxel Carcinoma, Non-… Lung Neoplasms Non-Small Cell … | for efficacy and safety reasons - | |||
| NCT01326117 Details | 2014-07-29 Interventional | 4 | 0 | Tadalafil Gastroparesis Vomiting Diabetic Gastro… Nausea | lack of patients who meet inclusion criteria; there was one screen failure - | |||
| NCT00005072 Details | 2014-07-29 Interventional | 1/2 | 25 | Interleukin-2 Prostatic Neopl… Prostate Cancer | Development in prostate cancer indication halted - | |||
| NCT00004050 Details | 2014-07-29 Interventional | 2 | 13 | Interleukin-2 Prostatic Neopl… Prostate Cancer | Development in prostate cancer indication halted - | |||
| NCT01151787 Details | 2014-07-25 Interventional | 3 | 35 | Amitriptyline Cyclobenzaprine Migraine Disord… Chronic Migrain… | Study was never initiated under new location/provider group. Contract to continue was never
signed between TEVA and Kennedy Headache Center - | |||
| NCT01078376 2009-013165-25 Details | 2014-07-25 Interventional | 1 | 29 | Azilsartan medo… Hypertension | Business Decision (see below) The study was discontinued without complete enrollment of Cohort 3. Therefore, PK modeling will be used to determine the appropriate doses in children 1 to <6 years of age, in lieu of completing Cohort 3. | |||
| NCT00429702 Details | 2014-07-25 Interventional | 2 | 7 | Dexamethasone Diphenhydramine Lorazepam Ondansetron Promethazine Nausea Vomiting Unspecified Chi… | Closed due to poor accrual and lack of feasibility to finish study per DSMB The study was closed prior to completing enrollment based on the recommendation by the SunCoast CCOP Research Base Data Safety Monitoring Board for a lack of feasibility and poor enrollment. | |||
| NCT00184054 Details | 2014-07-25 Interventional | 2 | 11 | Arsenic Trioxid… Ascorbic Acid Leukemia Leukemia, Myelo… Leukemia, Myelo… Acute Myelogeno… | Competing studies - | |||
| NCT01021943 Details | 2014-07-24 Interventional | 2 | - | Spironolactone Kidney Transpla… | - - | |||
| NCT00925548 2008-005544-17 Details | 2014-07-24 Interventional | 3 | 16 | Cyclophosphamid… Breast Neoplasm… Breast Cancer | See termination reason in the below Purpose statement Efficacy data were not analyzed as the trial was prematurely terminated following the clinical hold on the investigational new drug application for tecemotide (L-BLP25) | |||
| NCT00373204 Details | 2014-07-24 Interventional | 2 | 50 | Motexafin gadol… Carcinoma, Non-… Lung Neoplasms Lung Cancer | - - | |||
| NCT01534949 Details | 2014-07-23 Interventional | 1 | 1 | Rituximab Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Diffuse Large B… | - - | |||
| NCT00957242 Details | 2014-07-23 Interventional | 3 | 145 | Warfarin Fibrosis Idiopathic Pulm… Pulmonary Fibro… | Excess of mortality in the treatment group created safety concerns. - | |||
| NCT00851552 Details | 2014-07-21 Interventional | 2 | 9 | Bortezomib Doxorubicin Liposomal doxor… Rituximab Lymphoma Lymphoma, Large… | Lack of sponsor support Due to the study's early termination and inadequate number of patients, no patients were analyzed. | |||
| NCT00545948 Details | 2014-07-21 Interventional | 2 | 31 | Cisplatin Pemetrexed Vinorelbine Carcinoma, Non-… | Study terminated due to reproducibility issues with genomics prediction model. - | |||
| NCT00224419 Details | 2014-07-21 Interventional | 4 | [1 Refs] | 181 | Nicotine Pregnancy Smoking | was terminated due to meeting a priori stopping rule set by DSMB - |